{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-003832","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.310249+00:00","generated_at":"2026-05-28T05:07:55.358534+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"4D Molecular reports positive 32-week DME data; FDA aligns on single Phase 3; cash runway into 2028","bullets":["Cash, equivalents, securities $506M as of Dec 31; cash runway extended to 2028.","SPECTRA Part 1 (DME): 4D-150 well tolerated, no intraocular inflammation; high dose +8.4 letters BCVA, -194 µm CST; mean 0.6 supplemental injections vs 4.0 for aflibercept.","FDA: single Phase 3 trial (300-400 patients) acceptable for BLA for 4D-150 in DME; SPECTRA Part 2 no longer needed.","Pipeline refocus: core 4D-150 (wet AMD/DME) and 4D-710 (CF); discontinue 4D-110 and 4D-125; reduce investment in 4D-175/725/310 pending partnerships.","Phase 3 4FRONT trials for wet AMD start Q1 and Q3 2025; topline data expected H2 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-003832","json":"https://secwatch.observer/filing/0000950170-25-003832.json","markdown":"https://secwatch.observer/filing/0000950170-25-003832.md","text":"https://secwatch.observer/filing/0000950170-25-003832.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000095017025003832/0000950170-25-003832-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000095017025003832/fdmt-20250110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:07:55.358534+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}